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Drug utilization studyAim: To compare the prevalence and trends of antipsychotic drug use during pregnancy between countries across
four continents.
Methods: Individually linked health data in Denmark (2000−2012), Finland (2005–2014), Iceland (2004–2017),
Norway (2005–2015), Sweden (2006–2015), Germany (2006–2015), Australia (New SouthWales, 2004–2012),
HongKong (2001–2015), UK (2006–2016), and theUS (Medicaid, 2000–2013, and IBMMarketScan, 2012–2015)
were used. Using a uniformed approach, we estimated the prevalence of antipsychotic use as the proportion of
pregnancies where a woman filled at least one antipsychotic prescription within threemonths before pregnancy
until birth. For the Nordic countries, data were meta-analyzed to investigate maternal characteristics associated
with the use of antipsychotics.
Results: We included 8,394,343 pregnancies. Typical antipsychotic use was highest in the UK (4.4%) whereas
atypical antipsychotic use was highest in the US Medicaid (1.5%). Atypical antipsychotic use increased over
time in most populations, reaching 2% in Australia (2012) and US Medicaid (2013). In most countries,
prochlorperazine was the most commonly used typical antipsychotic and quetiapine the most commonly used
atypical antipsychotic. Use of antipsychotics decreased across the trimesters of pregnancy in all populations ex-
cept Finland. Antipsychotic use was elevated among smokers and those with parity ≥4 in the Nordic countries.
Conclusion: Antipsychotic use during pregnancy varied considerably between populations, partly explained by
varying use of the typical antipsychotic prochlorperazine, which is often used for nausea and vomiting in early
pregnancy. Increasing usage of atypical antipsychotics among pregnantwomen reflects the pattern thatwas pre-
viously reported for the general population.
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).partment of Medicine Solna,
.V. This is an open access article und1. Introduction
Antipsychotic drugs are often prescribed as the standard of care for
schizophrenia, other psychotic disorders and bipolar disorder. Theyer the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
107J. Reutfors et al. / Schizophrenia Research 220 (2020) 106–115are also prescribed, but to a lesser degree, for depression, anxiety, in-
somnia, autism, as well as for nausea and vomiting in early pregnancy
(Halfdanarson et al., 2017; Minami et al., 2019; Toh et al., 2013). The
mechanism of action and indications differ to a varying degree between
typical (first generation) antipsychotics and the more recently intro-
duced atypical (second generation) antipsychotics. In general, atypical
antipsychotics have a stronger serotonin receptor antagonism, and are
used to treat mood disorders to a larger extent.
Discontinuation of antipsychotic treatment during pregnancy may
increase the risk of recurrence ofmental disorders including bipolar dis-
order (Viguera et al., 2007) and psychosis (Tosato et al., 2017). On the
other hand, potential risks associated with antipsychotic use during
pregnancy include metabolic disturbances, abnormal fetal growth
(Boden et al., 2012b), preterm birth (Lin et al., 2010), as well as congen-
ital anomalies (Huybrechts et al., 2016). However, findings to date are
not consistent and some increased risks for adverse outcomes may be
illness-rather than drug-related (Boden et al., 2012a). Thus, women
treated with antipsychotics and their clinicians, are faced with the com-
plex challenge of balancing the benefits and potential risks of antipsy-
chotic drug treatment during pregnancy.
Since the introduction of the first antipsychotic, chlorpromazine, in
the 1950s, various antipsychotics have been developed, and studies
have found increasing use of antipsychotics in the general population
in recent years (Halfdanarson et al., 2017; Olfson et al., 2012). At the
same time, a widening of both on- and off-label antipsychotic indica-
tions has been observed (Halfdanarson et al., 2017; Hojlund et al.,
2019). However, little is known about the worldwide patterns of anti-
psychotic use among pregnant women.
To enable international comparisons and to inform future studies in-
vestigating the benefits and risks associated with antipsychotic use in
pregnancy, our aimwas to describe antipsychotic drug use during preg-
nancy and the three months before by type of antipsychotic, trends in
prevalence and the characteristics of users in ten countries: Australia,
Denmark, Finland, Germany, Hong Kong, Iceland, Norway, Sweden,
the United Kingdom (UK), and the United States (US).
2. Methods
2.1. Study population
The study included pregnancies from 11 populations in 10 countries
with pregnancies ending in live births or stillbirths. The full population
is included in the Nordic countries data registries, while the datasets
from the other countries are selected samples. However, the German
and UK data sources are considered representative of their respective
populations, and the databases from Hong Kong, Australia, and the
two US databases combined, include the majority of the women giving
birth in their respective regions. The data sources are described in Panel
1 and below.
From the Nordic countries (Denmark, Finland, Iceland, Norway, and
Sweden) we used population-based birth and dispensed prescription
drug registers which were individually-linked using the civil personal
registration number, uniquely assigned to each resident at birth or im-
migration (Furu et al., 2010; Langhoff-Roos et al., 2014).
FromNew SouthWales (NSW), themost populous state in Australia,
we used population-based birth data and dispensed pharmaceutical
claims data which were probabilistically linked using identifiers
including name, address, and date of birth (Tran et al., 2017). The
study population was restricted to pregnancies among concessional
beneficiaries, eligible for reduced co-payments due to low income,
chronic illness, or disability, representing 20.3% of births in NSW,
2006–2012, for whom complete dispensing data are recorded.
From Germany, we used the German Pharmacoepidemiological Re-
searchDatabase (GePaRD)which is based on claims data from four stat-
utory health insurance providers, currently including information on
about 25 million persons from all geographical regions of Germany,representative of all persons with a statutory health insurance in
Germany, which is about 90% of the population.We identified pregnan-
cies from this database using an algorithm based on diagnostic and
health care codes (Wentzell et al., 2018).
From Hong Kong, we used the pregnancy cohort nested in the elec-
tronic health records of the Clinical Data Analysis and Reporting System
(CDARS), which covers health care services available to all residents in
Hong Kong (Lao et al., 2017). CDARS contains deterministic linkage of
the records of all in-patient, out-patient, and emergency room admis-
sions in hospital ambulatory clinics, drug prescription and dispensing,
through a unique patient identification number (Man et al., 2017).
From the UK, we used data from The Health Improvement Network
(THIN), a large primary care database that includes longitudinal clinical
and prescribing records from general practice and includes data from
about 6% of the UK population. Over 98% of the UK population is regis-
teredwith a general practitioner, and the register is broadly representa-
tive of the UK population (Petersen et al., 2017).
From the US, we included a pregnancy cohort nested within the
Medicaid Analytic eXtract (MAX) database which includes inpatient
and outpatient claims, as well as outpatient prescriptions dispensed
for publicly-insured individuals from 46 US states and theDistrict of Co-
lumbia (Palmsten et al., 2013). We also included a pregnancy cohort
nested within the IBM MarketScan© Commercial Claims and Encoun-
ters Database, which includes similar healthcare claims from
privately-insured individuals from all regions of the US (MacDonald
et al., 2019).
2.2. Drug exposure
Antipsychotic drugs were defined using theWorld Health Organiza-
tion Anatomical Therapeutic Chemical (ATC) classification codes
starting with N05A. Lithium (N05AN01) was excluded because it has a
different mechanism of action. Prochlorperazine (N05AB04) was not
captured in the data from Australia and Finland and was not approved
in Germany and Hong Kong. Typical and atypical antipsychotic drugs
were classified according to Supplementary Table 1.
Use of Antipsychotics any time during the pregnancy periodwas de-
fined by at least one filled prescription for an antipsychotic drug from
90 days before the first day of the last menstrual period (LMP) until
birth. We also classified use according to trimester including the
three-month pre-pregnancy period (up to 90 days before LMP), first tri-
mester (T1 = 0–97 days of gestation), second trimester (T2 =
98–202 days of gestation), and third trimester (T3 = 203
days of gestation to birth). The trimester definitionsused in the Finn-
ishdatawere as follows: T1=0–84, T2=85–182, and T3=183 days of
gestation to birth.
2.3. Data analysis
The prevalence of antipsychotic use (any, typical, atypical) was cal-
culated as the proportion of pregnancies in each population where the
woman had filled at least one prescription for an antipsychotic drug
from 90 days before the first day of LMP and throughout the whole
pregnancy period. We described prevalence by maternal age category
and by trimester. To assess the relative change in use of antipsychotics
across calendar years,we calculated the prevalence ratioswith 95% con-
fidence intervals (CI) between the first and last year of available data for
each population by antipsychotic class, with the first year as the refer-
ence. In addition, linear time trends in prevalence were calculated
using linear regression models. The resulting linear regression estimate
(β) can be interpreted as the average percentage point change in prev-
alence per year.
Further, among each population we identified the five most com-
monly dispensed antipsychotics in the first and last year of available
data. As prochlorperazine is almost exclusively used as an antiemetic
during pregnancy (Fiaschi et al., 2019), we performed sub-analyses
Panel 1
Study populations and data source characteristics.
Country and
years of
coverage
Data sources and study populations Pregnancies included Drug information available
Australia,
New South
Wales
(NSW)
2004–2012
a) NSW Perinatal Data Collection (state-wide
birth register)
b) Pharmaceutical Benefits Scheme (national
claims data)
Publicly insured
All pregnancies resulting in live birth or stillbirth from 20 weeks of
gestation or birthweight of at least 400 g
Only pregnancies among women who were concessional beneficiaries
(eligible for increased subsidy for prescription drugs) were included
All dispensed, subsidised
prescription drugs in outpatient
care and private hospitals
Denmark
2000–2012
a) Medical Birth Register b) National
Prescription Registry
(National health registers)
Publicly insured
All pregnancies resulting in live birth or stillbirth from 22 weeks of
gestation
All dispensed prescription drugs
in outpatient care
Finland
2005–2014
a) Medical Birth Register b) Register of
Reimbursed Drug Purchases and Register of
Medical Special Reimbursements
(National health registers)
Publicly insured
All pregnancies resulting in live birth or stillbirth from 22 weeks of
gestation
All dispensed, reimbursed
prescription drugs in outpatient
care
Germany
2006–2015
German Pharmacoepidemiological Research
Database (GePaRD) (Healthcare claims
database)
Publicly insured
All pregnancies resulting in live birth or stillbirth (N500 g) All dispensed, reimbursed
prescription drugs in outpatient
care
Hong Kong
2001–2015
Clinical Data Analysis and Reporting System
(CDARS)
All pregnancies in public hospitals resulting in live birth or stillbirth are
directly identified in the database.
All dispensed prescription drugs
in public in- and outpatient care
Iceland
2004–2017
a) Medical Birth Register
b) National Medicine Registry
(National health registers)
Publicly insured
All pregnancies resulting in live birth or stillbirth from 22 weeks of
gestation
All dispensed prescription drugs
in outpatient care
Norway
2005–2015
a) Medical Birth Registry of Norway
b) Norwegian Prescription Database
(National health registers)
Publicly insured
All pregnancies resulting in a live birth or stillbirth from 12 weeks of
gestation
All dispensed prescription drugs
in outpatient care
Sweden
2006–2015
a) Medical Birth Register
b) Prescribed Drug Register
(National health registers)
Publicly insured
All pregnancies resulting in a live birth or stillbirth from 22 weeks of
gestation
All dispensed prescription drugs
in outpatient care
UK
2001–2015
The Health Improvement Network (THIN)
database
(Primary care database)
Publicly insured
All pregnancies identified based on the recorded birth date, the last
menstrual period and the estimated birth dates
All drugs prescribed in general
practice
US
MarketScan
2012–2015
IBM MarketScan® Commercial Claims and
Encounters (MarketScan) database
(Healthcare claims database)
Privately insured
All pregnancies in women continuously enrolled in their health plan
from before pregnancy until birth, identified with an ICD-9-based
algorithm to identify live births and stillbirths
All dispensed, reimbursed
prescription drugs in outpatient
care
US MAX
2000–2013
Medicaid Analytic eXtract (MAX) database
(Healthcare claims database)
Publicly insured
All pregnancies in women continuously enrolled in a state Medicaid
program from before pregnancy until birth, identified with an
ICD-9-based algorithm to identify live births
All dispensed, reimbursed
prescription drugs in outpatient
care
108 J. Reutfors et al. / Schizophrenia Research 220 (2020) 106–115excluding users of prochlorperazine from the estimated prevalence of
typical antipsychotics. We also analyzed the prevalence and trends of
prochlorperazine use separately.
For the Nordic countries, where data sources are similar, we further
present the use of antipsychotics by women's parity, smoking status,
and cohabitation. To this end, we meta-analyzed the prevalence esti-
mated from each Nordic country by weighting each population by the
inverse of the variance of the prevalence in the population
(Barendregt et al., 2013).
2.4. Ethical approvals
The study was approved by the following country specific institu-
tional review boards. Australia: The NSW Population and Health Ser-
vices Research Ethics Committee (2012/06/397) and the Australian
Institute of Health and Welfare Ethics Committee (2012/2/22).
Denmark: The Data Protection Agency (Record No. 2013-41-2569).
Finland: The Finnish Institute for Health and Welfare (THL/1551/
6.02.00/2018), The Social Insurance Institution of Finland (Kela 148/
52/2018) and Statistics Finland (TK-53-1870-18).
Germany: Studies based on GePaRD are exempt from institutional
review board review.
Hong Kong: The institutional review board of the University of Hong
Kong/Hospital Authority Hong Kong West Cluster (UW15-619)Iceland: The National Bioethics Committee (VSN-18-123).
Norway: The Norwegian Data Inspectorate and the Regional Com-
mittee for Medical and Health Research Ethics (REC-South East).
Sweden: The regional ethics review board in Stockholm, Sweden (N
2015/1826–31/2).
UK: The Health Improvement Network Scientific Review Committee
(18THIN072).
US: The institutional review board of Brigham and Women's Hospi-
tal for the Medicaid data and Harvard TH Chan School of Public Health
for the MarketScan data.
In the remaining participating countries, according to their respec-
tive regulations, no ethical approval was necessary for this study.
3. Results
The study included 8,394,343 pregnancies. Table 1 shows the preva-
lence of antipsychotic use in pregnancy by population, maternal age,
and antipsychotic class. The overall prevalence of antipsychotic use dur-
ing pregnancy ranged from 0.28% in Germany to 4.64% in the UK. The
use of typical and atypical antipsychotics was lowest in Germany
(0.12%) and Denmark (0.16%), respectively. The use of typical antipsy-
chotics was highest in the UK (4.42%), whereas the use of atypical anti-
psychotics was highest in the US Max population (1.53%). Young
women (≤24 years) had the highest use of typical antipsychotics in six
Table 1
Antipsychotic drug use during the pregnancy period by country and maternal age.
Total number of
pregnancies
Pregnancies with at least 1 filled prescription
of:
Any
antipsychotic
Typical
antipsychotic
Atypical
antipsychotic
N N (%) N (%) N (%)
Australia, NSW 2004–2012
All ages 148,462 2355 (1.59) 497 (0.33) 2020 (1.36)
≤24 years 50,573 635 (1.26) 110 (0.22) 559 (1.11)
25–34 years 73,399 1195 (1.63) 269 (0.37) 1017 (1.39)
≥35 years 24,480 523 (2.14) 119 (0.49) 443 (1.81)
Denmark 2000–2012
All ages 813,360 2858 (0.35) 1844 (0.23) 1269 (0.16)
≤24 years 87,014 458 (0.53) 307 (0.35) 211 (0.24)
25–34 years 485,356 1240 (0.26) 864 (0.18) 487 (0.10)
≥35 years 125,804 565 (0.45) 382 (0.30) 218 (0.17)
Finland 2005–2014
All ages 584,139 4374 (0.75) 977 (0.17) 3741 (0.64)
≤24 years 103,690 1114 (1.07) 166 (0.16) 1014 (0.98)
25–34 years 370,232 2372 (0.64) 549 (0.15) 2021 (0.55)
≥35 years 110,217 888 (0.81) 262 (0.24) 706 (0.64)
Germany 2006–2015
All ages 999,105 2842 (0.28) 1193 (0.12) 1912 (0.19)
≤24 years 80,050 369 (0.46) 165 (0.21) 241 (0.30)
25–34 years 616,444 1442 (0.23) 613 (0.10) 960 (0.16)
≥35 years 302,611 1031 (0.34) 415 (0.14) 711 (0.23)
Hong Kong 2001–2015
All ages 416,494 1408 (0.34) 910 (0.22) 705 (0.17)
≤24 years 43,205 187 (0.43) 113 (0.26) 110 (0.25)
25–34 years 269,014 744 (0.28) 490 (0.18) 357 (0.13)
≥35 years 104,274 477 (0.46) 307 (0.29) 238 (0.23)
Iceland 2004–2017
All ages 60,477 881 (1.46) 504 (0.83) 435 (0.55)
≤ 24 years 10,738 239 (2.23) 110 (1.02) 145 (1.05)
25–34 years 37,237 487 (1.31) 304 (0.82) 216 (0.41)
≥35 years 12,502 155 (1.24) 90 (0.72) 32 (0.41)
Norway 2005–2015
All ages 645,459 7492 (1.16) 6162 (0.95) 1539 (0.24)
≤ 24 years 103,305 1560 (1.51) 1236 (1.20) 378 (0.37)
25–34 years 418,034 4472 (1.07) 3772 (0.90) 809 (0.19)
≥35 years 124,120 1460 (1.18) 1154 (0.93) 352 (0.28)
Sweden 2006–2015
All ages 1,028,732 3929 (0.38) 2079 (0.20) 2097 (0.20)
≤24 years 148,042 731 (0.49) 367 (0.25) 423 (0.29)
25–34 years 654,477 2249 (0.34) 1243 (0.19) 1136 (0.17)
≥35 years 226,190 949 (0.42) 538 (0.24) 469 (0.21)
UK 2006–2016
All ages 767,251 35,577 (4.64) 33,884 (4.42) 2115 (0.28)
≤24 years 232,391 8427 (3.63) 8093 (3.48) 431 (0.19)
25–34 years 374,185 20,053 (5.36) 19,187 (5.13) 1096 (0.29)
≥35 years 160,675 7097 (4.42) 6604 (4.11) 588 (0.37)
US, MarketScan 2012–2015
All ages 859,505 6761 (0.79) 3371 (0.39) 3514 (0.41)
≤24 years 134,218 1905 (1.42) 688 (0.51) 1261 (0.94)
25–34 years 532,887 3485 (0.65) 2007 (0.38) 1534 (0.29)
≥35 years 192,400 1371 (0.71) 676 (0.35) 719 (0.37)
US, MAX 2000–2013
All ages 2,071,359 66,820 (3.23) 37,200 (1.80) 31,712 (1.53)
≤24 years 1,180,493 34,530 (2.93) 19,626 (1.66) 15,741 (1.33)
25–34 years 752,111 27,241 (3.62) 15,151 (2.01) 13,109 (1.74)
≥35 years 138,755 5049 (3.64) 2423 (1.75) 2862 (2.06)
Note: The pregnancy period is defined as 90 days before the date of the last menstrual pe-
riod to the date of birth.
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Sweden, and US MarketScan) and of atypical antipsychotics in eight
populations (Denmark, Finland, Germany, Hong Kong, Iceland,
Norway, Sweden, and US MarketScan).Fig. 1 a,b, and c show the trends in antipsychotic use in pregnancy by
calendar year and population and Supplementary Table 2 shows the ac-
companying prevalence ratios and CIs. When comparing the first and
last year of available data, overall antipsychotic use increased in six pop-
ulations (Australia, Denmark, Finland, Germany, Iceland, and UK), with
the largest increase in Finland (3.63-fold from 2005 to 2014) and
Australia (2.34-fold from 2004 to 2012) (Suppl. Table 2). Overall anti-
psychotic use decreased in three populations (Norway, Sweden, and
US Max).
The prevalence of typical antipsychotic use increased in the UK, was
stable in three populations (Australia, Denmark, Iceland), and decreased
in the other seven populations (Suppl. Table 2). Atypical antipsychotic
use increased in all populations except in Iceland and US MarketScan
(Fig. 1c: Suppl. Table 2).
Fig. 2a to e present the prevalence of antipsychotic drug use in the
pre-pregnancy period and by trimester in each population. The overall
use of antipsychotics was highest in the pre-pregnancy period in six
populations and in the first trimester in the remaining five populations
(Fig. 2a). For typical antipsychotics, a slightly higher use in the pre-
pregnancy period was found in four populations (Australia, Denmark,
Germany, and Hong Kong), whereas the use was markedly higher in
the first trimester in six populations (Iceland, Norway, Sweden, UK, US
MarketScan, and US MAX) (Fig. 2b). The use of typical antipsychotics
declined from the first to the third trimester in all populations except
for Finland, where prochlorperazine was not captured (Fig. 2b). For
atypical antipsychotics, the use was highest 90 days before pregnancy
in all populations, and thereafter decreased throughout pregnancy.
Prochlorperazine was approved and captured in seven popula-
tions (Denmark, Iceland, Norway, Sweden, UK, US MarketScan, and
US MAX). In these, its use decreased over time except in UK where
its use nearly doubled (Suppl. Table 2, Suppl. Fig. 1a). When the
prochlorperazine users were excluded, a decreasing trend for typical
antipsychotics was seen in six out of the eleven populations (Finland,
Germany, Hong Kong, Norway, Sweden, and US MarketScan; Suppl.
Table 2, Suppl. Fig. 1b). Prochlorperazine use accounted for a large
proportion of the use of typical antipsychotics in five populations
(Iceland, Norway, UK, US MarketScan, and US MAX) (Fig. 2b and e),
but the pattern of declining use over the trimesters remained after
excluding the prochlorperazine users (Fig. 2e).
Table 2 presents the five most commonly dispensed antipsy-
chotics in the pregnancy period in the first and last year of available
data by population. Atypical antipsychotics dominated in the most
recent year in all populations, except that prochlorperazine contin-
ued to be the most commonly used antipsychotic in Norway, UK,
and US. In the most recent year, quetiapine was the most commonly
used atypical antipsychotic drug in all populations, followed by
olanzapine in six populations and by aripiprazole in five populations.
The proportion of pregnancies exposed to atypical antipsychotics in-
creased markedly over time in all populations with quetiapine
reaching 1.35% in Australia and 0.94% in Finland at the end of the
study period.
Table 3 presents the prevalence of antipsychotic use among preg-
nant women in the Nordic countries by demographic and pregnancy-
related characteristics. Antipsychotic use was more prevalent among
women with higher parity, reaching 0.92% for any antipsychotic
amongwomenwith parity of four ormore. Furthermore, the prevalence
of antipsychotic use was 1.46% in smokers versus 0.43% among non-
smokers during pregnancy, and both typical and atypical antipsychotic
use was higher in smokers.
4. Discussion
4.1. Key results
In our study of over eight million pregnancies with data from
2000 to 2017 in ten countries (eleven populations), applying a
Fig. 1. a–c Trends in antipsychotic drug use during the pregnancy period by population per year. The pregnancy period is defined as 90 days before the date of the lastmenstrual period to
thedate of birth. Fig. 1aAny antipsychotic druguse bypopulation. Fig. 1b Typical antipsychotic druguse bypopulation. Fig. 1c Atypical antipsychotic druguse bypopulation. Abbreviations:
AU= New South Wales, Australia; DK= Denmark; FI = Finland; DE= Germany; HK= Hong Kong; IS = Iceland; NO = Norway; SE = Sweden; GB = United Kingdom; US-MS = US
MarketScan; US-MAX= US MAX. The y-axis scales for each country are different, and the trends in antipsychotic drug use should be interpreted accordingly.
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ing the pregnancy period varied considerably between countries.
The highest prevalence of typical antipsychotics was observed in
the UK (4.42%, driven by the use of prochlorperazine) and of atyp-
ical antipsychotics in the US Max population (1.53%). In most pop-
ulations, the use of typical antipsychotics decreased or was stable,
whereas atypical antipsychotic use increased over time. Use of an-
tipsychotics decreased with each trimester of pregnancy in most
populations.4.2. Interpretation & comparison with other studies
Factors whichmay explain differences in antipsychotic use between
the countries include varying clinical practices reflecting different
guidelines (Graham et al., 2018), pricing policies and reimbursement
practices which may influence physicians' prescribing patterns. There
may also be differences in what proportion of the actual antipsychotic
medication is distributed from outpatient pharmacies as opposed to di-
rectly from psychiatric or other clinics. Furthermore, the prevalence of
Fig. 2. a–e Prevalence of antipsychotic drug use during the pregnancy period by trimester and population. The pregnancy period is defined as 90 days before the date of the last menstrual
period to the date of birth.
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Table 2
Five most commonly dispensed antipsychotic drugs during the pregnancy period in the first and last year of available data by population.
Rank Antipsychotic  % of all APa users 
% of all 
pregnancies Rank Antipsychotic  
% of all 
APa 
users 
% of all 
pregnancies 
Australia 2004    2012   
1 Olanzapine   36.94 0.36 1 Quetiapine   59.02 1.35 
2 Risperidone   20.38 0.20 2 Olanzapine   24.59 0.56 
3 Quetiapine   17.83 0.17 3 Risperidone   9.84 0.22 
4 Chlorpromazine 13.38 0.13 4 Aripiprazole   5.46 0.12 
5 Haloperidol   10.19 0.10 5 Chlorpromazine 3.83 0.09 
Denmark 2006    2013   
1 Flupentixol   18.47 0.04 1 Quetiapine   39.87 0.21 
2 Zuclopenthixol   17.83 0.04 2 Chlorprothixene  24.12 0.13 
3 Levomepromazine   15.29 0.04 3 Perphenazine   17.04 0.09 
4 Chlorprothixene  10.83 0.03 4 Aripiprazole   8.04 0.04 
5 Perphenazine   9.55 0.02 5 Olanzapine   7.40 0.04 
Finland 2005    2014   
1 Quetiapine   23.89 0.08 1 Quetiapine   81.37 0.94 
2 Olanzapine   18.89 0.06 2 Olanzapine   9.92 0.11 
3 Perphenazine   16.67 0.05 3 Aripiprazole   6.41 0.07 
4 Risperidone   11.67 0.04 4 Risperidone   4.43 0.05 
5 Chlorprothixene   8.89 0.03 5 Perphenazine   3.05 0.04 
Germany 2006    2015   
1 Olanzapine 18.89 0.05 1 Quetiapine 47.86 0.15 
2 Fluspirilene 17.97 0.04 2 Aripiprazole 12.03 0.04 
3 Quetiapine 10.14 0.03 3 Pipamperone 9.36 0.03 
4 Perazine 9.22 0.02 4 Olanzapine 8.56 0.03 
5 Risperidone 9.22 0.02 5 Risperidone 8.02 0.03 
Hong Kong 2001    2015   
1 Haloperidol 25.00 0.09 1 Quetiapine 38.20 0.17 
2 Chlorpromazine 50.00 0.18 2 Haloperidol 20.22 0.09 
3 Trifluoperazine 25.00 0.09 3 Olanzapine 16.85 0.08 
4 Thiridazine 25.00 0.09 4 Risperidone 16.85 0.08 
5  - - - 5 Trifluoperazine 16.29 0.07 
Iceland 2004    2017   
1 Prochlorperazine   70.97 1.10 1 Quetiapine   50.00 0.88 
2 Quetiapine   8.06 0.13 2 Perphenazine   32.86 0.58 
3 Chlorpromazine 8.06 0.13 3 Olanzapine 11.43 0.20 
4 Levomepromazine   4.84 0.08 4 Levomepromazine   7.14 0.13 
5 Risperidone 3.23 0.05 5 Flupentixol   4.29 0.08 
Norway 2005    2015   
1 Prochlorperazine   48.97 0.72 1 Prochlorperazine   41.53 0.45 
2 Chlorpromazine 19.15 0.28 2 Quetiapine   27.32 0.29 
3 Levomepromazine   13.82 0.20 3 Levomepromazine   10.86 0.12 
4 Dixyrazine   8.97 0.13 4 Olanzapine   7.51 0.08 
5 Chlorprothixene  5.21 0.08 5 Chlorprothixene  5.43 0.06 
Sweden 2006    2015   
1 Dixyrazine   72.52 0.77 1 Quetiapine   45.06 0.18 
2 Prochlorperazine   9.54 0.02 2 Olanzapine   22.99 0.09 
3 Olanzapine   6.30 0.01 3 Aripiprazole   12.87 0.05 
4 Risperidone   4.01 0.01 4 Prochlorperazine   10.80 0.04 
5 Levomepromazine   3.05 0.01 5 Levomepromazine   8.74 0.03 
UK 2006    2016   
1 Prochlorperazine   92.88 2.93 1 Prochlorperazine   91.39 5.71 
2 Olanzapine   1.86 0.06 2 Quetiapine   5.68 0.35 
3 Chlorpromazine 1.82 0.06 3 Aripiprazole   1.69 0.11 
4 Quetiapine   1.61 0.05 4 Olanzapine   1.48 0.09 
5 Flupentixol   1.40 0.04 5 Chlorpromazine 0.91 0.06 
US MarketScan 2012    2015   
1 Prochlorperazine   48.66 0.40 1 Prochlorperazine   44.91 0.35 
2 Aripiprazole   20.49 0.17 2 Quetiapine   22.66 0.18 
3 Quetiapine   19.90 0.16 3 Aripiprazole   17.36 0.14 
4 Risperidone   5.60 0.05 4 Lurasidone 6.44 0.05 
5 Olanzapine   3.27 0.03 5 Risperidone   5.93 0.05 
US MAX 2000    2013   
1 Prochlorperazine   80.93 2.88 1 Prochlorperazine   37.89 1.18 
2 Olanzapine   7.97 0.28 2 Quetiapine   23.70 0.74 
3 Risperidone   6.19 0.22 3 Aripiprazole   20.93 0.65 
4 Quetiapine   3.65 0.13 4 Risperidone   11.71 0.37 
5 Haloperidol   1.86 0.07 5 Olanzapine   4.67 0.15 
Note: The pregnancy period is defined as 90 days before the date of the last menstrual period to the date of birth.
Annotation: Antipsychotic names in light gray = typical antipsychotic; white = atypical antipsychotic; dark gray = typical antipsychotic usually used as an antiemetic.
aAP = Antipsychotic.
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Table 3
Pooled prevalence of antipsychotic drug use during the pregnancy period in the Nordic countries by maternal and pregnancy characteristics.
Country (weight %) Total Any antipsychotic Typical antipsychotic Atypical antipsychotic
N Prevalence (95% CI)a N Prevalence (95% CI)a N Prevalence (95% CI)a
Pooled (100) 3,132,167 19,534 0.58 (0.58, 0.59) 11,566 0.32 (0.31, 0.33) 9081 0.27 (0.26, 0.27)
Denmark (26.0) 813,360 2858 0.35 (0.34, 0.36) 1844 0.23 (0.22, 0.24) 1269 0.16 (0.15, 0.16)
Iceland (1.9) 60,477 881 1.46 (1.36, 1.55) 504 0.83 (0.76, 0.91) 435 0.72 (0.65, 0.79)
Finland (18.7) 584,139 4374 0.75 (0.73, 0.77) 977 0.17 (0.16, 0.18) 3741 0.64 (0.62, 0.66)
Norway (20.6) 645,459 7492 1.16 (1.13, 1.19) 6162 0.95 (0.93, 0.98) 1539 0.24 (0.23, 0.25)
Sweden (32.8) 1,028,732 3929 0.38 (0.37, 0.39) 2079 0.20 (0.19, 0.21) 2097 0.20 (0.20, 0.21)
Parity
1 1,299,079 7580 0.55 (0.54, 0.56) 4497 0.30 (0.29, 0.31) 3583 0.27 (0.26, 0.28)
2 1,004,582 5177 0.47 (0.45, 0.48) 3600 0.34 (0.33, 0.35) 1782 0.16 (0.16, 0.17)
3 381,385 2553 0.62 (0.60, 0.65) 1781 0.41 (0.39, 0.43) 895 0.22 (0.21, 0.24)
≥4 169,324 1604 0.92 (0.87, 0.96) 1053 0.57 (0.53, 0.60) 658 0.38 (0.36, 0.41)
Missing 277,797 2620 0.93 (0.90, 0.97) 635 0.21 (0.19, 0.23) 2163 0.21 (0.19, 0.23)
Smokingbc
No 2,551,171 11,892 0.43 (0.42, 0.44) 7411 0.24 (0.24, 0.25) 4953 0.18 (0.18, 0.19)
Yes 341,726 5123 1.46 (1.42, 1.50) 2448 0.68 (0.65, 0.71) 3198 0.86 (0.83, 0.89)
Missing 178,793 1638 0.88 (0.84, 0.92) 1203 0.62 (0.58, 0.65) 495 0.27 (0.24, 0.29)
Cohabitationb
Cohabiting 1,876,289 8653 0.49 (0.48, 0.50) 3930 0.20 (0.20, 0.21) 5368 0.33 (0.32, 0.34)
Not cohabiting 516,888 2721 0.50 (0.48, 0.52) 1172 0.39 (0.38, 0.41) 1750 0.65 (0.63, 0.66)
Missing 93,531 668 0.70 (0.65, 0.75) 302 0.36 (0.32, 0.39) 424 1.06 (1.03, 1.08)
Multi-fetal pregnancy
No 3,077,982 19,231 0.58 (0.58, 0.59) 11,392 0.34 (0.33, 0.35) 8939 0.27 (0.26, 0.27)
Yes 53,052 302 0.54 (0.48, 0.60) 174 0.31 (0.26, 0.36) 142 0.23 (0.19, 0.27)
Year of birth
2000-2004c 323,511 852 0.26 (0.24, 0.27) 712 0.21 (0.20, 0.23) 179 0.23 (0.19, 0.27)
2005–2009 1,285,897 8695 0.64 (0.62, 0.65) 6457 0.44 (0.43, 0.45) 2730 0.20 (0.20, 0.21)
2010–2017 1,522,759 9987 0.61 (0.59, 0.62) 4397 0.23 (0.22, 0.24) 6172 0.37 (0.36, 0.38)
Note: The pregnancy period is defined as 90 days before the date of the last menstrual period to the date of birth.
a Prevalence per 100 pregnancies weighted by population and 95% confidence intervals (CI).
b Data on smoking available for Denmark, Finland, Norway, Sweden; Data on cohabitation available for Denmark, Iceland, Finland, Sweden; For Denmark’ Cohabiting’ reflects marital
status.
c Only Denmark and Iceland included births occurring in 2000–2004.
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US, there was a notably higher antipsychotic use among the publicly-
insured (MAX) than the privately-insured (MarketScan) women. This
may be because the publicly-insured US MAX population includes
women with low economic resources, in whom psychiatric disorders
are more prevalent (Kasper, 1986). This interpretation should also be
applied to the Australian estimates. It may also be partly due to our in-
clusion of prochlorperazine, as lower rates reported previously from US
MAXdid not include thatmedication (Park et al., 2017). Perceptions and
attitudes among the mentally ill and care providers regarding the value
of antipsychotics (Morrison et al., 2015; Velligan et al., 2009) may also
differ. Finally, some classification differences may apply. For example,
in Australia, prochlorperazine is classified as an antiemetic (ATC
A04AD) instead of as an antipsychotic and was therefore not included
in the study data.
Previous reports regarding patterns of antipsychotic drug use among
pregnant women come from a number of country-specific studies. A
study of data from 11 different private health plans from 2001 to 2007
in the US, found a stable prevalence of 0.09% for typical antipsychotics
but an increasing trend from 0.33% to 0.82% for atypical antipsychotics
(Toh et al., 2013). Similar patterns were reported in both a Tennessee
Medicaid study (Epstein et al., 2013), and a previous Medicaid MAX
study covering 2001 to 2010, which partly overlap with our study
(Park et al., 2017). Also spanning different time periods, data from
some of the other data sources included in this study have also been re-
ported in country-specific studies previously. Thus, in THIN data (UK)
from 1995 to 2007, 0.29% of women were prescribed antipsychotics in
the six months before they became pregnant and 0.19% of women
after the first six weeks of pregnancy, with an overall time trend of
increasing use of atypical antipsychotics whereas that of typical an-
tipsychotics decreased (Petersen et al., 2014). In Hong Kong, from
2004 to 2014, the prevalence of antipsychotic use in pregnancy in-
creased from 0.18% to 0.27% (Lao et al., 2017). Our data from theUK and Hong Kong cover more recent years, and for the US we in-
clude a broader population, yet these trends have persisted. In
Denmark, a prevalence of antipsychotic use of 0.20% was reported
among pregnant women from 1997 to 2012 (Ingstrup et al., 2018)
and in Norway, 1% of pregnant women used antipsychotics (includ-
ing lithium) from 2005 to 2015 (Engeland et al., 2018). Time trends
were not reported in these studies, but our analyses of data for sim-
ilar time periods found increasing use of atypical antipsychotics also
in Denmark and Norway.
During the study period, new atypical antipsychotics were
marketed and indications were expanded, which together with off-
label use (Alexander et al., 2011;Maher and Theodore, 2012) and re-
moval of some older typical antipsychotics (e.g. dixyrazine) from
the market in certain countries, may explain the increase in use of
atypical antipsychotics in our study populations. Atypical antipsy-
chotics have increasingly been recommended as treatment for bipo-
lar disorder and as add-on treatment for unipolar depression,
especially with quetiapine, olanzapine, and aripiprazole (Kennedy
et al., 2016). Further, atypical antipsychotics may be preferred be-
cause of safety concerns regarding antiepileptics as mood stabilizers
in women with bipolar disorder during pregnancy (Petersen et al.,
2017). Quetiapine was the most commonly dispensed atypical anti-
psychotic in all countries, possibly partly due to off-label use for in-
dications such as insomnia (McKean and Monasterio, 2012), with a
similar pattern of increasing use found for aripiprazole. Our findings
for pregnant women mirror the trend of increasing use of atypical
antipsychotics in the general population worldwide (Halfdanarson
et al., 2017).
For typical antipsychotics, use was clearly most common in the
first trimester, especially in countries where prochlorperazine use
was captured. Prochlorperazine is almost exclusively used as an an-
tiemetic (Fiaschi et al., 2019), and nausea and vomiting is usually
most pronounced in the first trimester (Louik et al., 2006). Our
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their antipsychotic prescriptions, or physicians stopped prescribing,
during the second and third trimester. This corroborates findings for
antipsychotics in the UK in both the CPRD and THIN databases
(Margulis et al., 2014; Petersen et al., 2014), Sweden in 2007
(Stephansson et al., 2011), and in the Sentinel system in the US
(Illoh et al., 2018). Even after removing the women who were pre-
scribed prochlorperazine, the pattern of decreased use remained as
the pregnancies progressed. A similar pattern has also been observed
for antidepressants (Illoh et al., 2018; Stephansson et al., 2011;
Zoega et al., 2015). Discontinuation of psychotropic medication dur-
ing pregnancy is common due to concerns that fetal exposure to
these medication may have harmful effects for the child (Einarson
et al., 2001), although the data regarding antipsychotics are not yet
conclusive (Huybrechts et al., 2016). Some women who filled anti-
psychotic prescriptions in the first trimester may not yet have been
aware that they were pregnant, and the pregnancy may have been
unintended (Finer and Zolna, 2016). It could be speculated that stop-
ping the use of antipsychotics during the latter part of pregnancy
may decrease the risk of delayed neural development and pregnancy
complications, including gestational diabetes. On the other hand,
there is a high risk of relapse for those who discontinue medication
for schizophrenia (Lin et al., 2010) and bipolar disorder (Viguera
et al., 2007; Yonkers et al., 2004), and untreated psychiatric illness
may confer health risks both for the mother and unborn child, as
well as for the child after birth (Boden et al., 2012a; Gentile, 2017).
In the Nordic countries we found that pregnant womenwith four or
more previous deliveries had the highest antipsychotic use, which was
not explained by age; there was an inverse association between anti-
psychotic use and age. Pregnantwomenwho smoked during pregnancy
had a higher prevalence of typical and atypical antipsychotic use than
non-smoking women, similar to findings reported for SSRIs and SNRIs
(Zoega et al., 2015). This was expected since the rate of smoking is
much higher among individuals with mental disorders (de Leon and
Diaz, 2005; Jimenez-Solem et al., 2013). The finding may imply that
women with mental disorders have a different pattern of risk factors
of adverse outcomes, pointing to the need to control for such factors
in future studies evaluating outcomes in relation to antipsychotic med-
ication during pregnancy.4.3. Limitations
Limitations that are inherent in the observational design include cir-
cumstances that may have led to overestimation of use because the
analyses were based on prescriptions or dispensing of antipsychotic
medication for which the adherence to treatment is not known. Under-
estimation of antipsychotic use may also have occurred since antipsy-
chotic medication dispensed directly to the women by hospitals or
other clinics were not captured, or because they were not reimbursed
antipsychotics; the latter was the case for prochlorperazine in
Australia and Finland. The underlying indication for the prescribed anti-
psychotics was not available in the study data. Further, the databases
differ in their set up and collection of data, with the Nordic countries
providing data for the whole population, whereas the data from the
non-Nordic countries were selected samples to varying degrees but
are still considered representative of their country's pregnant popula-
tion (Panel 1). For Finland, the first trimester was shorter than for the
other countries, which may have affected the proportion of use during
T1; however, this is not expected to affect the overall conclusions of
the study which are not related to the investigation of outcomes during
a specific exposure period. Finally, a limitation of our study is that coun-
tries had different time periods of data availability for antipsychotic use
during pregnancy, but we consider it unlikely that the main patterns
and trends identified in this study would change in the countries with
fewer years of follow-up.5. Conclusion
In summary, this study found that the prevalence of antipsychotic
drug use varied between populations, partly driven by variations in
the capture of prochlorperazine mainly used for nausea in early preg-
nancy. The use of antipsychotics was highest pre-pregnancy and at the
beginning of the pregnancy. Most countries showed an increasing
trend for use of atypical antipsychotics. This reflects the pattern in the
general population, and demonstrates the worldwide uptake of newer
antipsychotic medication, also in pregnant women.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.schres.2020.03.048.
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